Grannus Therapeutics is pioneering advancements in cancer treatment by focusing on the selective inhibition of the Hsp90β isoform, a strategy that addresses the limitations of previous pan-Hsp90 inhibitors. These earlier inhibitors targeted all four isoforms of Hsp90, leading to significant on-target toxicities and disappointing efficacy, which ultimately resulted in a lack of FDA approvals for over 20 molecules tested in clinical trials since the early 2000s. By developing a first-in-class Hsp90β-selective inhibitor, Grannus aims to provide a treatment option with a cleaner toxicity profile and demonstrated in-vivo efficacy, making it a promising candidate for addressing multiple solid tumors.

The foundation of Grannus Therapeutics is built on the innovative research conducted by Notre Dame scientists, Dr. Brian Blagg and Dr. Sanket Mishra, alongside biotech executive John Foglesong. Their collaborative efforts have led to the creation of a novel therapeutic approach that not only mitigates the adverse effects associated with pan-Hsp90 inhibitors but also enhances the potential for effective cancer treatment. The company is well-positioned to advance its pipeline of products, leveraging its unique technology to improve patient outcomes in oncology.

United States

Grannus is a biotech startup based on the technological discoveries of Notre Dame Scientists Dr. Brian Blagg and Dr. Sanket Mishra, and the administration of pharmaceutical company that has the... Meanwhile, McDonnell has high-profile.

Grannus Therapeutics

Company Details